These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 26505995)
1. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. Gill SJ; Travers J; Pshenichnaya I; Kogera FA; Barthorpe S; Mironenko T; Richardson L; Benes CH; Stratton MR; McDermott U; Jackson SP; Garnett MJ PLoS One; 2015; 10(10):e0140988. PubMed ID: 26505995 [TBL] [Abstract][Full Text] [Related]
2. PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. Engert F; Schneider C; Weiβ LM; Probst M; Fulda S Mol Cancer Ther; 2015 Dec; 14(12):2818-30. PubMed ID: 26438158 [TBL] [Abstract][Full Text] [Related]
3. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019 [TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ Clin Cancer Res; 2015 Feb; 21(4):819-32. PubMed ID: 25500058 [TBL] [Abstract][Full Text] [Related]
6. PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview. Adibi A; Tokat ÜM; Özgü E; Aydın E; Demiray İ; Demiray M Ther Adv Med Oncol; 2023; 15():17588359231213841. PubMed ID: 38107827 [TBL] [Abstract][Full Text] [Related]
7. [PARP inhibitors--theoretical basis and clinical application]. Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117 [TBL] [Abstract][Full Text] [Related]
8. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Liu X; Shi Y; Guan R; Donawho C; Luo Y; Palma J; Zhu GD; Johnson EF; Rodriguez LE; Ghoreishi-Haack N; Jarvis K; Hradil VP; Colon-Lopez M; Cox BF; Klinghofer V; Penning T; Rosenberg SH; Frost D; Giranda VL; Luo Y Mol Cancer Res; 2008 Oct; 6(10):1621-9. PubMed ID: 18922977 [TBL] [Abstract][Full Text] [Related]
9. Ewing sarcoma protein promotes dissociation of poly(ADP-ribose) polymerase 1 from chromatin. Lee SG; Kim N; Kim SM; Park IB; Kim H; Kim S; Kim BG; Hwang JM; Baek IJ; Gartner A; Park JH; Myung K EMBO Rep; 2020 Nov; 21(11):e48676. PubMed ID: 33006225 [TBL] [Abstract][Full Text] [Related]
14. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448 [TBL] [Abstract][Full Text] [Related]
15. Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor. Yamasaki H; Miyamoto M; Yamamoto Y; Kondo T; Watanabe T; Ohta T Genes Cells; 2016 Aug; 21(8):852-60. PubMed ID: 27353471 [TBL] [Abstract][Full Text] [Related]
16. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813 [TBL] [Abstract][Full Text] [Related]
17. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Boulton S; Kyle S; Durkacz BW Carcinogenesis; 1999 Feb; 20(2):199-203. PubMed ID: 10069454 [TBL] [Abstract][Full Text] [Related]
18. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937 [TBL] [Abstract][Full Text] [Related]
19. Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells. Wang H; Zhang S; Song L; Qu M; Zou Z Oncogene; 2020 Apr; 39(14):2905-2920. PubMed ID: 32029902 [TBL] [Abstract][Full Text] [Related]
20. XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. Hirota K; Ooka M; Shimizu N; Yamada K; Tsuda M; Ibrahim MA; Yamada S; Sasanuma H; Masutani M; Takeda S Genes Cells; 2022 May; 27(5):331-344. PubMed ID: 35194903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]